PYC pyc therapeutics limited

targeting intracellular proteins, page-7

  1. 11,715 Posts.
    lightbulb Created with Sketch. 1543
    Hi Wayne,

    Thanks. Yes, very interesting article.

    You wrote;

    Remember how Phylogica have selected a series of cell penetrating peptides that bind with Fibronectin. In fact, the binding is so exquisite that Fibronectin actually enhances delivery.

    Yes, I do and that they have more structural diversity :-)

    Recall also that Centyrin is an Alternative Scaffold designed from the Fibronectin Type 111 (FN3) domain.

    Yes, indeed. And that all antibody & scaffold companies are displaying diversity within one structural theme.

    The hope is that the EEP will not only improve the efficiency of release of the cargo but that it will create a powerful synergy of action.

    Quite plausible Wayne.

    I keep coming back to Phylogica's structurally diverse peptide library as to what will set them apart from the pack.

    Refer page 56 of this presentation;

    http://www.phylogica.com/media/Phylogica_Technical-May-2013-.pdf

    Tony



 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.45
Change
-0.005(0.34%)
Mkt cap ! $842.8M
Open High Low Value Volume
$1.45 $1.46 $1.40 $451.6K 315.0K

Buyers (Bids)

No. Vol. Price($)
1 10001 $1.43
 

Sellers (Offers)

Price($) Vol. No.
$1.45 3114 1
View Market Depth
Last trade - 16.10pm 08/07/2025 (20 minute delay) ?
PYC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.